Home Health Care Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA...

Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

14
0
SHARE

A company developing targeted therapies for cancers expects to complete submission of data for one of its drugs in lung cancer by the end of the first quarter, based on top-line data from a trial of patients whose disease carries a particular genetic anomaly.

Cambridge, Massachusetts-based Blueprint Medicines said Wednesday that it had started a rolling submission to the Food and Drug Administration for the drug BLU-667 (pralsetinib), based on data from its Phase I/II study in patients with RET fusion-positive non-small cell lung cancer.

Shares of the company were up about 1.8% on the Nasdaq following the news. The company also plans to submit for regulatory approval of the drug in medullary thyroid cancer in the second quarter of 2020.

Blueprint is one of multiple companies developing RET inhibitors. Its most advanced competitor is Indianapolis-based Eli Lilly’s Loxo Oncology division, whose RET inhibitor LOXO-292 (selpercatinib) has also shown positive data in RET-positive NSCLC, per an announcement by the company in September, while also being tested in other cancers that carry the mutation. Lilly acquired Loxo last year for $8 billion.

In its Wednesday announcement, Blueprint said that pralsetinib showed a 61% overall response rate in 80 patients who had received prior platinum-based chemotherapy, and the median duration of response had not yet been reached. Overall, 95% of patients had tumor shrinkage, with 14% showing complete regression of tumors. Among 26 patients who had not received prior treatment, the overall response rate was 73%, including a 12% complete response rate. The drug was deemed well-tolerated, with most side effects being mild to moderate.

In a note to investors in September, following Lilly’s announcement, Cowen analysts expressed a positive view toward selpercatinib, but wrote that pralsetinib remains competitive, with Lilly’s drug not appearing clearly superior to Blueprint’s, as proposed points of differentiation appeared to weaken with each data update. The most recent data for selpercatinib, in 105 NSCLC patients, showed an overall response rate of 68%, with a 20.3-month median duration of response and 18.4-month median progression-free survival. Meanwhile, an analysis of 34 patients who had not received prior therapy showed an 85% overall response rate.

Photo: Donald Miralle, Getty Images

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

one + 6 =